Biology subjects

Koren, J.

Publications and source records attributed to Koren, J..

5 recordsLinked to original sources

bioRxiv2026

Testis-Specific MAGEA3/6 Regulate Glycolysis to Promote Metabolic Flexibility and Reveal Therapeutic Vulnerabilities in Pancreatic Cancer Cells

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor characterized by metabolic plasticity that enables cancer cells to survive nutrient deprivation and therapeutic stress. Melanoma-associated antigens A3 and A6 (MAGEA3/6), members of the cancer-testis antigen family with a previously identified protective role in spermatogenesis during nutritional stress, have been implicated in cancer progression and metabolic regulation. However, their contribution to metabolic adaptation in pancreatic cancer remains poorly understood. Here, we investigated the molecular mechanisms underlying MAGEA3/6-mediated resistance to glycolytic inhibition using complementary gain- and loss-of-function models, pharmacological inhibition of metabolic pathways, cellular metabolic assays, and integrated transcriptomic, proteomic, metabolomic, and lipidomic analyses. MAGEA3/6 expression enhanced resistance to 2-deoxy-D-glucose (2-DG), with MAGEA6-expressing MIA PaCa-2 cells exhibiting a greater than 2.5-fold increase in the half-maximal inhibitory concentration (IC50). Conversely, MAGEA3/6 depletion reduced clonogenic growth and migration and increased sensitivity to 2-DG. Resistance persisted despite pharmacological inhibition of mTORC1, the pentose phosphate pathway, or glutaminase, suggesting metabolic adaptations beyond these pathways. Unexpectedly, MAGEA6 expression was associated with increased rather than decreased AMPK1 protein abundance, contrasting with previously reported MAGEA3/6-mediated AMPK degradation and suggesting context-dependent regulation of this master regulator of cellular metabolism. MAGEA6 also reduced hexokinase HK1 and HK2 abundance while increasing several downstream glycolytic enzymes, revealing discordant regulation of glycolysis. Seahorse analyses and integrated multi-omics profiling identified extensive remodeling of mitochondrial metabolism, glutamine-aspartate metabolism, phospholipid composition, lipid storage, and redox homeostasis. Interestingly, despite enhanced resistance to glycolytic inhibition, MAGEA6-expressing cells exhibited increased sensitivity to hydrogen peroxide-induced oxidative stress, revealing a potential metabolic vulnerability. Given that MAGEA3/6 are physiologically expressed primarily in the male germline during early spermatogenesis, a process highly sensitive to metabolic and oxidative stress, these findings also raise important questions about their physiological roles in protecting developing germ cells and maintaining metabolic and redox homeostasis. Together, our findings recognize MAGEA3/6 as regulators of metabolic plasticity in PDAC and highlight how understanding their molecular functions in both spermatogenesis and cancer may uncover previously unrecognized metabolic vulnerabilities and potential therapeutic opportunities.

cancer biology↗

bioRxiv2026

The atypical cadherin CELSR2 regulates distinct epithelial-mesenchymal states and oxidative phosphorylation in triple-negative breast cancer

Triple-negative breast cancer (TNBC) is characterized by marked intratumoral heterogeneity, which contributes to metastatic dissemination, therapeutic resistance, and poor clinical outcome. Epithelial-mesenchymal plasticity is a major contributor to this heterogeneity. Identifying the molecular regulators governing epithelial-mesenchymal plasticity is therefore essential to understanding how distinct tumor cell populations arise and fuel TNBC progression. Here, we identify the adhesion G protein-coupled receptor CELSR2 as an independent poor-prognosis marker and regulator of epithelial-mesenchymal plasticity in TNBC. Spatial transcriptomic analyses revealed segregation of CELSR2high tumor cells within the epithelial tumor core and CELSR2low tumor cells at the invasive front. In line with the latter observation, CELSR2 expression decreases during EMT and its loss promotes acquisition of a hybrid epithelial-mesenchymal state. CELSR2high tumor cells display a CREB-associated oxidative phosphorylation (OXPHOS) program and promote cell proliferation and primary tumor growth. Conversely, CELSR2low cells display features of a more migratory phenotype. Collectively, our findings identify CELSR2 as a previously unknown regulator of epithelial-mesenchymal plasticity and reveal that heterogeneous CELSR2 expression shapes spatially and functionally distinct tumor cell populations, thereby contributing to intratumoral heterogeneity in TNBC.

cancer biology↗

bioRxiv2025

Progressive Supranuclear Palsy PERK haplotype B selectively translates DLX1 promoting tau toxicity

The unfolded protein response (UPR) sensor PERK exists in two haplotypes termed A and B. PERK-B uniquely confers increased risk for tauopathies like progressive supranuclear palsy (PSP), but the mechanisms distinguishing its function from PERK-A and contributing to its association with tau pathology are not known. Here, we developed a controlled cellular model for a pair-wise comparison of the two PERK haplotypes, finding their UPR functions nearly indistinguishable. However, a careful examination employing puromycin-based proteomics revealed that a subset of mRNA translation events were permissible under PERK-B, but not PERK-A, dependent UPR. Critically, one of the targets that escaped PERK-B suppression was the transcription factor DLX1, which has been genetically linked to PSP risk. Here, we found a shift in the solubility of DLX1 in human PSP brain tissue, and report that silencing of DLX-1 reduced the aggregation of tau in mammalian cells. Furthermore, silencing of the fly homolog of DLX1 was sufficient to decrease tau-induced toxicity, in vivo. Our results detail the haplotype-specific PERK-B/DLX-1 pathway as a novel driver of tau pathology in cells, flies, and likely human brain, revealing new insights into PSP pathogenesis and potential therapeutic targets.

neuroscience↗

bioRxiv2022

Brain mapping and spatial protein profiling reveal functional connectivity deficits and molecular changes following repetitive mild traumatic brain injury in wild-type mice.

Repetitive mild traumatic brain injury (rmTBI) is a leading and severe threat to cognition that often goes undiagnosed. A major challenge in developing diagnostics and treatments for the consequences of rmTBI is the fundamental knowledge gaps that explain how rmTBI promotes brain dysfunction. It is both critical and urgent to understand the neuropathological and functional consequences of rmTBI to develop effective therapeutic strategies. In this study, we sought to define the extent of altered brain functional connectivity (FC) and expression of neuropathological markers after rmTBI. We performed two rmTBI (2x 0.6{square}J impacts 24{square}h apart) in male and female C57BL/6J wild-type (WT) (~2.5-3mo) mice using closed head injury model of engineered rotational acceleration (CHIMERA) or sham procedures. At 5-6 days post-injury (dpi), we measured changes in brain volume and FC using T2-weighted images, resting-state functional MRI (rsfMRI), and graph theory analyses. We used diffusion tensor imaging (DTI) to assess microstructural changes in white matter tracts. In addition, at 7dpi, we measured changes in Iba1 and GFAP to determine the extent of gliosis. The expression of disease-associated protein markers in grey and white matter regions were evaluated using the NanoString-GeoMx digital spatial protein profiling (DSP) platform. The rsfMRI data revealed aberrant changes in connectivity such as node clustering coefficient, global and local efficiency, participation coefficient, eigenvector centrality, and betweenness centrality in thalamus and other key brain regions that process visual, auditory, and somatosensory information. In addition, DTI revealed significantly decreased fractional anisotropy (FA) and axial diffusivity in the optic tract. Also, mean, radial, and axial diffusivity (L1) were significantly increased in the hippocampus. DSP revealed that phospho-serine 199 tau (pS199) as well as glial markers such as GFAP, cathepsin-D, and Iba1 were significantly increased in the optic tract. In thalamic nuclei, the neuroinflammatory marker GPNMB was increased significantly, and the cell proliferation marker Ki-67 was decreased in the rmTBI group. Our data suggest that rmTBI significantly alters brain functional connectivity and causes a profound inflammatory response in gray matter regions, beyond chronic white matter damage.

neuroscience↗

bioRxiv2020

Novel therapeutic targets to mitigate early neuronal dysfunction and cognitive deficits in tauopathy

Tauopathies are a group of more than twenty known disorders that involve progressive neurodegeneration, cognitive decline, and pathological tau accumulation. Current therapeutic strategies provide only limited, late-stage symptomatic treatment. This is partly due to lack of understanding of the molecular mechanisms linking tau and cellular dysfunction, especially during the early stages of disease progression. In this study, we treated early stage tau transgenic mice with a multi-target kinase inhibitor to identify novel substrates that contribute to cognitive impairment and exhibit therapeutic potential. Drug treatment significantly ameliorated brain atrophy and cognitive function as determined by behavioral testing and a sensitive imaging technique called manganese-enhanced magnetic resonance imaging (MEMRI) with quantitative R1 mapping. Surprisingly, these benefits occurred despite unchanged hyperphosphorylated tau levels. To elucidate the mechanism behind these improved cognitive outcomes, we performed quantitative proteomics to determine the altered protein network during this early stage in tauopathy and compare this model with the human AD proteome. We identified a cluster of preserved pathways shared with human tauopathy with striking potential for broad multi-target kinase intervention. We further report high confidence candidate proteins as novel therapeutically relevant targets for the treatment of tauopathy. One Sentence SummaryMulti-target kinase inhibition rescues cognitive function in early stage tauopathy mice and reverses proteomic shifts common to Alzheimers disease in humans.

neuroscience↗